Kintor Pharma Completes Enrollment for KX-826 Phase III Trial for Male Androgenetic Alopecia in China

29 March 2023 | Wednesday | News


Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults
Image Source : Public Domain

Image Source : Public Domain

The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-regional study designed to evaluate the efficacy and safety of 5mg (0.5% concentration) twice daily (BID) KX-826 for treating male AGA adults in China. Professor Zhang Jianzhong from Peking University People's Hospital and Professor Yang Qinping from Huashan Hospital Affiliated to Fudan University are the leading principal investigators (leading PIs) of this trial. The primary endpoint for the clinical trial is the change from baseline in non-vellus target area hair counts (TAHC) after 24 weeks of treatment in comparison to placebo. The safety endpoints mainly include the type, incidence and severity of adverse events.

On 8 September 2021, the company announced that the primary endpoint of Phase II clinical trial of KX-826 for male AGA adults in China was met. After 24 weeks of treatment, the TAHC in the 5mg (0.5% concentration) BID KX-826 group increased by 15.34/cm2 compared with the placebo group from baseline, with a statistical difference (P=0.024). On 1 December 2022, the company announced that the primary endpoint of Phase II clinical trial of KX-826 for female AGA adults in China was met. After 24 weeks of treatment, the TAHC in the 5 mg (0.5% concentration) once daily (QD) KX-826 group increased by 11.39/cmcompared with the placebo group from baseline, with a statistical difference (P=0.0087). KX-826 has showed a good safety profile in both trials. In addition, the Phase II clinical trial of KX-826 for the treatment of male AGA adults in the US has completed the enrollment of all subjects in August 2022, and the company expects to release the top-line data in the second quarter of 2023.

Dr. Youzhi Tong, founder, Chairman and Chief Executive Officer of Kintor Pharma, commented, "We would like to thank all the PIs from 26 centers and the company's medical and clinical operations staff for their joint efforts to finish the subjects enrollment under the challenges of COVID-19 pandemic. This is another important milestone we have achieved following that the Phase II trials of KX-826 for male and female AGA in China have reached the primary endpoints, respectively. The company will continue to move forward the execution of 24-week study plus 4-week safety follow-up assessment with high quality, and expect to release the top-line data in Q4 2023. If the data is positive, we would proceed with the NDA application with the China NMPA. Meanwhile, the company is planning for KX-826's MRCT studies and actively pursuing licensing-out opportunities. We believe that KX-826 would benefit hair loss people around the globe."

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close